UK markets open in 2 hours 55 minutes
  • NIKKEI 225

    26,732.45
    +562.15 (+2.15%)
     
  • HANG SENG

    23,606.45
    -200.55 (-0.84%)
     
  • CRUDE OIL

    87.02
    +0.41 (+0.47%)
     
  • GOLD FUTURES

    1,797.40
    +4.30 (+0.24%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • BTC-GBP

    27,761.64
    +809.91 (+3.01%)
     
  • CMC Crypto 200

    843.35
    +23.85 (+2.91%)
     
  • ^IXIC

    13,352.78
    -189.34 (-1.40%)
     
  • ^FTAS

    4,230.83
    +38.13 (+0.91%)
     

Antiseptics and Disinfectants Market Report Up to 2031: Visiongain Research Inc

·5-min read

Visiongain has published a new report on Antihypertensives Market Report to 2031. Market is segmented by type (Diuretics, Beta-blockers, ACE inhibitors, Angiotensin II receptor blockers, calcium channel blockers, Others) By end user (Retail Pharmacy, Hospitals, Others) By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antihypertensives Companies. PLUS COVID-19 Recovery Scenarios.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/antihypertensives-market/#download_sampe_div

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Surge in geriatric population and increasing prevalence of high blood pressure or hypertension globally are some of the factors driving the growth of the global antihypertensives market.

COVID-19 Impact on the Global Antihypertensives Market
The global pandemic (COVID-19) is caused due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which binds target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. The patients with hypertension along with COVID‐19 are at higher risk. However, the patients without antihypertensive treatment are significantly at higher risk of mortality.

Market Driver
Change in lifestyle, increasing obese population
Controlling blood pressure is of significant health priority to reduce the serious health condition associated with hypertension, which includes strokes, heart failure, stroke, and end‐stage renal failures. Obesity is considered as the major factor to develop hypertension. The change in lifestyle such as inactivity, high calorie intake, leads to obesity. According to WHO, more than 1.9 billion people were overweight in 2016. About 41.0% of obese Americans have hypertension, however, the change in lifestyle is recommended for hypertension patients. The change in lifestyle & increasing incidences of obesity, enhance the demand for antihypertensives in the market.

Increasing prevalence of high blood pressure or hypertension globally.
The hypertension is associated with the risk strokes, heart disease, which are considered as the leading causes of mortality in the US. Hypertension as a primary or contributing cause in US, which nearly accounts half a million deaths. Hypertension is uncontrolled in about 50% of the more than one third of Americans older than 20 years. However, only about 1 in 4 adults (24%) with hypertension have under control condition.

Market Opportunity

High growth of hypertensives in developing economies
Hypertension is a serious medical condition, which significantly increases the risks of heart, kidney, and other diseases. As per WHO, it is estimated about 1.13 billion people have hypertension, out of which two-thirds of the population lives in low- and middle-income countries. The modifiable risk factors associated with hypertensives includes obesity, consumption of alcohol, physical inactivity, whereas the non- modifiable factors include ageing, family history of hypertension, co-existing diseases such as diabetes or kidney disease. Most of the increasing hypertensive cases are highly seen in low- and middle-income countries.

Get Detailed TOC @ https://www.visiongain.com/report/antihypertensives-market/#download_sampe_div

Competitive Landscape
Pfizer Inc., Novartis AG, Merck & Co., Inc, Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd, Johnson & Johnson, AstraZeneca PLC, AbbVie, Cipla Limited, Sun Pharmaceutical Industries Ltd., Sanofi are some of the key players contributing to the growth of the global antihypertensives market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

For instance, June 2019, Mankind Pharma launched Zolahart (Azilsartan), antihypertensive drug at affordable price. The company introduce the drug & focuses to reduce commonly related disease of hypertension. Azilsartan, a new generation anti-hypertensive drug, which is safe to use in hypertensive patients with comorbid conditions such as diabetes or Chronic Kidney Disease.

In April 2019, Cipla Limited announced final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan drug from the United States Food and Drug Administration (US FDA). The drug is endothelin receptor antagonist indicated to treat pulmonary arterial hypertension.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.


To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Antihypertensives market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting